Abstract: Human rabies monoclonal antibodies (rabies MAbP) comprising rabies human MAb S057 heavy chain and light chain subunits are expressed and assembled in plants under the control of two strong constitutive promoters. Additionally, regulatory control elements such as alfalfa mosaic virus untranslated leader sequence and Lys-Asp-Glu-Leu (KDEL) endoplasmic reticulum retention signal were linked at the N- and C-terminus of the heavy chain of human rabies MAbP, respectively to regulate expression of the rabies MAbP. Rabies MAbP was as effective at neutralizing the activity of the rabies virus as the mammalian-derived antibody (MAbM) or human rabies immunoglobulin (HRIG).

Abstract: Provided are methods and compositions for treating hepatitis virus infections in mammals, especially humans. The methods comprise (1) administering N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds in combination with nucleoside antiviral agents, nucleotide antiviral agents, mixtures thereof, or immunomodulating/immunostimulating agents, or (2) administering N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds in combination with nucleoside antiviral agents, nucleotide antiviral agents, or mixtures thereof, and immunomodulating/immunostimulating agents.

Abstract: Provided are methods and compositions for treating hepatitis virus infections in mammals, especially humans. The methods comprise (1) administering N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds in combination with nucleoside antiviral agents, nucleotide antiviral agents, mixtures thereof, or immunomodulating/immunostimulating agents, or (2) administering N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds in combination with nucleoside antiviral agents, nucleotide antiviral agents, or mixtures thereof, and immunomodulating/immunostimulating agents.

Abstract: Compounds of formula (I): wherein R represents various substituent groups, are useful as inhibitors of glucosylceramide synthase.

Abstract: The present invention relates to compositions and methods for treating obesity. In particular, this invention describes the use of imino sugars, such as N-butyldeoxynojirimycin (NB-DNJ) for appetite suppression, thereby causing weight loss.

Abstract: Provided are methods and compositions for treating hepatitis virus infections in mammals, especially humans. The methods comprise (1) administering N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds alone or in combination with nucleoside antiviral agents, nucleotide antiviral agents, mixtures thereof, or immunomodulating/immunostimulating agents, or (2) administering N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds alone or in combination with nucleoside antiviral agents, nucleotide antiviral agents, or mixtures thereof, and immunomodulating/immuno-stimulating agents.

Abstract: Compositions and methods of treatment of interferon-responsive disorders are provided wherein the methods, for example, comprise orally administering a composition which comprises a therapeutically effective amount of at least one alkylated imino sugar having an alkylated side chain, and a pharmaceutically acceptable carrier.

Abstract: The present invention describes a novel tyrosinase protein and methods of use thereof. Specifically, the invention provides tyrosinase derived peptides and polynucleotides, and their ability to elicit an immune response and treat a melanoma.

Abstract: The invention as described herein provides compositions and methods for cancer immunotherapy and cancer detection. In particular, the invention discloses plant-derived human monoclonal antibodies that bind human carcinoma antigens in cancer cell lines.

Abstract: A method for treating a glycolipid storage-related disorder, comprising administering a therapeutically effective amount of an inhibitor of glycolipid synthesis in combination with an agent capable of increasing the rate of glycolipid degradation or in combination with bone marrow transplantation. Inhibitors of glycolipid synthesis include N-butyldeoxynojirimycin (NB-DNJ), N-butyldeoxygalactonojirimycin (NB-DGJ) or N-nonyldeoxynojirimycin (NN-DNJ). Glycolipid storage-related disorders include Gaucher disease, Sandhoff's disease, Fabry's disease, Tay-Sach's disease, Niemann-Pick C storage disease, GM1 gangliosidosis, genetic disorders in which neuronal glycolipid accumulation contributes to disease pathology.

Abstract: The present invention relates to the treatment of viral infections, particularly HBV and HCV infections, with a combination comprising a vaccine against a virus antigen and compounds that inhibit glucosidase activity in the host cell.

Abstract: Provided are methods and compositions for treating hepatitis virus infections in mammals, especially humans. The methods comprise (1) administering N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds alone or in combination with nucleoside antiviral agents, nucleotide antiviral agents, mixtures thereof, or immunomodulating/immunostimulating agents, or (2) administering N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds alone or in combination with nucleoside antiviral agents, nucleotide antiviral agents, or mixtures thereof, and immunomodulating/immuno-stimulating agents.

Abstract: Compounds of formula (I): 1

Abstract: A combination drug therapy is disclosed for the treatment of a patient affected with Gaucher's disease or other such glycolipid storage diseases. The method comprises administering to said patient a therapeutically effective amount of both a N-alkyl derivative of deoxynojirimycin (DNJ) and a glucocerebrosidase enzyme to alleviate or inhibit the glycolipid storage disease. The alkyl group has from about two to about 20 carbon atoms and preferably is butyl, nonyl or decyl.

Abstract: Provided are methods and compositions for treating hepatitis virus infections in mammals, especially humans. The methods comprise (1) administering N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds in combination with nucleoside antiviral agents, nucleotide antiviral agents, mixtures thereof, or immunomodulating/immunostimulating agents, or (2) administering N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds in combination with nucleoside antivirals agents, nucleotide antiviral agents, or mixtures thereof, and immunomodulating/immunostimulating agents.

Abstract: The present invention provides a method by which to reversibly render male mammals infertile. Thus, the disclosed N-substituted imino compounds, and pharmaceutical compositions thereof, completely impair the fertility of male mammals, but exhibit no effect on that of female mammals, and are thus useful as male contraceptives.

Abstract: Methods for treating lipid storage diseases using compounds that inhibit glucosyltransferase enzymes are disclosed herein. The invention relates to the treatment of lipid storage disease with compounds that inhibit glucosyltransferase activity in the affected cells. It relates particularly to the use of 1,5-dideoxy-1,5-imino-D-glucitol and derivatives thereof.

Abstract: A novel method is disclosed for the treatment of a patient affected with Gaucher's disease or other such glycolipid storage diseases. The method comprises administering to said patient a therapeutically effective amount of a long-chain N-alkyl derivative of deoxynojirimycin to alleviate or inhibit the glycolipid storage disease. The long-chain alkyl group has from nine to about 20 carbon atoms and preferably is nonyl or decyl.

Abstract: Methods for treating lipid storage diseases using compounds that inhibit glucosyltransferase enzymes are disclosed herein. The invention relates to the treatment of lipid storage disease with compounds that inhibit glucosyltransferase activity in the affected cells. It relates particularly to the use of 1,5-dideoxy-1,5-imino-D-glucitol and derivatives thereof.

Abstract: The use of pH-sensitive liposomes enhances the delivery of drugs that target the endoplasmic reticulum, reducing the required dosage compared to direct administration of the drug without such liposomes. In particular, antiviral compounds such as N-butyldeoxynojirnmycin can be used in lower amounts when administered in a pH-sensitive liposome.